3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
4
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Melanoma
1
Liver Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
4
spartalizumab
3
Nivolumab
2
tislelizumab
1
obinutuzumab
1
naptumomab estafenatox
1
durvalumab
1
Topotecan
1
Polymerase Chain Reaction
1
Mass Spectrometry
1
In Situ Hybridization, Fluorescence
1
Immunohistochemistry
1
Gemcitabine
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
In Situ Hybridization, Fluorescence
×
Thoracic
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled